As drug costs for US employers rise, some cut GLP-1s from pl...
Pharmacy now represents 25% of employer healthcare spending, and employers are turning to DTC models and nontraditional PBMs to cut costs.
Revolution's ASCO showstopper gets FDA greenlight
The RAS inhibitor for pancreatic cancer that received a standing ovation at ASCO for its doubling of overall survival now has its FDA approval.
Spyre deprioritises arthritis drug after Phase 2 results
Spyre Therapeutics’ hopes for its anti-TL1A antibody SPY072 in rheumatoid arthritis (RA) have hit a bump in the road.
Jazz secures FDA approval for Ziihera in first-line HER2-pos...
Jazz Pharmaceuticals has been granted US approval for two combinations of its cancer drug Ziihera HER2+ advanced GEA.
Entropy, UCSF Pre-CTA for Ph2 psilocin vs Lexapro in MDD
Entropy signs Pre-CTA with UCSF to develop a US-based Phase 2 trial comparing IV psilocin treatment directly against escitalopram (Lexapro) in MDD.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
The MFN effect: what payers expect and how Pharma should res...
A live webinar and audience Q&A with practical insights from global payer research and leading payer experts
The Pharmaceutical Launch Excellence Summit
Where pharma leaders share strategies for successful drug launches.
Inizio Launches Connected Insights to Transform Global Medic...
Expanded APAC expertise, enhanced global infrastructure, and AI-enabled innovation to help life sciences organizations
9th Lab Asset & Facility Management Summit
Enabling Leaner, Smarter & More Resilient R&D Labs
The Evolution Summit Announces September 2026 Program for Cl...
Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.